Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older

J. Craig Nelson, Steven B. Hollander, James Betzel, Philip Smolen, M. Agronin, R. Bermingham, J. Bertino, D. Chess, K. Cranmer, R. Detrinis, L. Gelman, J. Hawa, E. C. Irvin, N. Kopyt, M. Levy, V. Marchello, L. Miller, S. Reddy-Pasem, K. Rapp, A. Rosanwo & 7 others C. Salzman, S. Segal, M. Shepard, A. Siegal, D. Tomas, L. Usher, C. K. Watt

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Introduction: Treatment studies of depression in the very oldest patients are infrequent. For these reasons, this study of mirtazapine orally disintegrating tablets was carried out in nursing home residents ≥85 years old with physician-diagnosed depression. The naturalistic conditions of the study allowed us to include patients with cognitive impairment, concomitant medications and comorbid illness. Methods: This was a subgroup analysis of nursing home residents ≥85 years old who took part in a larger 12-week open-label trial. Patients were eligible if they had physician-diagnosed depression, and a Mini-Mental State Exam score ≥ 10. The physician or nurse coordinator obtained data from Healthcare professionals in daily contact with the patient to complete the Clinical Global Impression (CGI) scale, a modified 16-item Hamilton Depression Scale (HAM-D), and the Cornell Scale for Depression in Dementia (CSDD). Treatment-emergent adverse events were recorded. Results: Of the 50 patients enrolled at 23 sites, 72% completed the 12-week trial. The mean age of the participants was 89.3 years. The mean HAM-D score declined from 16.9 at baseline to 7.3 at endpoint (ITT, LOCF analysis) For the CSDD, the mean score declined from 15.1 to 7.1. The percentage of responders on the CGI-Improvement (CGI-1) scale increased at each assessment reaching 55% at endpoint. Only 10% of the patients discontinued treatment because of adverse events. There was a mean increase in weight of 1.32 lbs (0.6 kg) at day 84. Conclusion: Although lacking a placebo control, this naturalistic study suggests that mirtazapine orally disintegrating tablets were effective and well tolerated in this sample of depressed nursing home residents ≥85 years of age.

Original languageEnglish
Pages (from-to)898-901
Number of pages4
JournalInternational Journal of Geriatric Psychiatry
Volume21
Issue number9
DOIs
StatePublished - Sep 1 2006

Fingerprint

Nursing Homes
Tablets
Depression
Physicians
Dementia
mirtazapine
Therapeutics
Nurses
Placebos
Delivery of Health Care
Weights and Measures

Keywords

  • Late life depression
  • Mirtazapine
  • Nursing home

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Nelson, J. C., Hollander, S. B., Betzel, J., Smolen, P., Agronin, M., Bermingham, R., ... Watt, C. K. (2006). Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. International Journal of Geriatric Psychiatry, 21(9), 898-901. https://doi.org/10.1002/gps.1589

Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. / Nelson, J. Craig; Hollander, Steven B.; Betzel, James; Smolen, Philip; Agronin, M.; Bermingham, R.; Bertino, J.; Chess, D.; Cranmer, K.; Detrinis, R.; Gelman, L.; Hawa, J.; Irvin, E. C.; Kopyt, N.; Levy, M.; Marchello, V.; Miller, L.; Reddy-Pasem, S.; Rapp, K.; Rosanwo, A.; Salzman, C.; Segal, S.; Shepard, M.; Siegal, A.; Tomas, D.; Usher, L.; Watt, C. K.

In: International Journal of Geriatric Psychiatry, Vol. 21, No. 9, 01.09.2006, p. 898-901.

Research output: Contribution to journalArticle

Nelson, JC, Hollander, SB, Betzel, J, Smolen, P, Agronin, M, Bermingham, R, Bertino, J, Chess, D, Cranmer, K, Detrinis, R, Gelman, L, Hawa, J, Irvin, EC, Kopyt, N, Levy, M, Marchello, V, Miller, L, Reddy-Pasem, S, Rapp, K, Rosanwo, A, Salzman, C, Segal, S, Shepard, M, Siegal, A, Tomas, D, Usher, L & Watt, CK 2006, 'Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older', International Journal of Geriatric Psychiatry, vol. 21, no. 9, pp. 898-901. https://doi.org/10.1002/gps.1589
Nelson, J. Craig ; Hollander, Steven B. ; Betzel, James ; Smolen, Philip ; Agronin, M. ; Bermingham, R. ; Bertino, J. ; Chess, D. ; Cranmer, K. ; Detrinis, R. ; Gelman, L. ; Hawa, J. ; Irvin, E. C. ; Kopyt, N. ; Levy, M. ; Marchello, V. ; Miller, L. ; Reddy-Pasem, S. ; Rapp, K. ; Rosanwo, A. ; Salzman, C. ; Segal, S. ; Shepard, M. ; Siegal, A. ; Tomas, D. ; Usher, L. ; Watt, C. K. / Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. In: International Journal of Geriatric Psychiatry. 2006 ; Vol. 21, No. 9. pp. 898-901.
@article{2dc649335bba4aae99b92a9149db0df7,
title = "Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older",
abstract = "Introduction: Treatment studies of depression in the very oldest patients are infrequent. For these reasons, this study of mirtazapine orally disintegrating tablets was carried out in nursing home residents ≥85 years old with physician-diagnosed depression. The naturalistic conditions of the study allowed us to include patients with cognitive impairment, concomitant medications and comorbid illness. Methods: This was a subgroup analysis of nursing home residents ≥85 years old who took part in a larger 12-week open-label trial. Patients were eligible if they had physician-diagnosed depression, and a Mini-Mental State Exam score ≥ 10. The physician or nurse coordinator obtained data from Healthcare professionals in daily contact with the patient to complete the Clinical Global Impression (CGI) scale, a modified 16-item Hamilton Depression Scale (HAM-D), and the Cornell Scale for Depression in Dementia (CSDD). Treatment-emergent adverse events were recorded. Results: Of the 50 patients enrolled at 23 sites, 72{\%} completed the 12-week trial. The mean age of the participants was 89.3 years. The mean HAM-D score declined from 16.9 at baseline to 7.3 at endpoint (ITT, LOCF analysis) For the CSDD, the mean score declined from 15.1 to 7.1. The percentage of responders on the CGI-Improvement (CGI-1) scale increased at each assessment reaching 55{\%} at endpoint. Only 10{\%} of the patients discontinued treatment because of adverse events. There was a mean increase in weight of 1.32 lbs (0.6 kg) at day 84. Conclusion: Although lacking a placebo control, this naturalistic study suggests that mirtazapine orally disintegrating tablets were effective and well tolerated in this sample of depressed nursing home residents ≥85 years of age.",
keywords = "Late life depression, Mirtazapine, Nursing home",
author = "Nelson, {J. Craig} and Hollander, {Steven B.} and James Betzel and Philip Smolen and M. Agronin and R. Bermingham and J. Bertino and D. Chess and K. Cranmer and R. Detrinis and L. Gelman and J. Hawa and Irvin, {E. C.} and N. Kopyt and M. Levy and V. Marchello and L. Miller and S. Reddy-Pasem and K. Rapp and A. Rosanwo and C. Salzman and S. Segal and M. Shepard and A. Siegal and D. Tomas and L. Usher and Watt, {C. K.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1002/gps.1589",
language = "English",
volume = "21",
pages = "898--901",
journal = "International Journal of Geriatric Psychiatry",
issn = "0885-6230",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older

AU - Nelson, J. Craig

AU - Hollander, Steven B.

AU - Betzel, James

AU - Smolen, Philip

AU - Agronin, M.

AU - Bermingham, R.

AU - Bertino, J.

AU - Chess, D.

AU - Cranmer, K.

AU - Detrinis, R.

AU - Gelman, L.

AU - Hawa, J.

AU - Irvin, E. C.

AU - Kopyt, N.

AU - Levy, M.

AU - Marchello, V.

AU - Miller, L.

AU - Reddy-Pasem, S.

AU - Rapp, K.

AU - Rosanwo, A.

AU - Salzman, C.

AU - Segal, S.

AU - Shepard, M.

AU - Siegal, A.

AU - Tomas, D.

AU - Usher, L.

AU - Watt, C. K.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Introduction: Treatment studies of depression in the very oldest patients are infrequent. For these reasons, this study of mirtazapine orally disintegrating tablets was carried out in nursing home residents ≥85 years old with physician-diagnosed depression. The naturalistic conditions of the study allowed us to include patients with cognitive impairment, concomitant medications and comorbid illness. Methods: This was a subgroup analysis of nursing home residents ≥85 years old who took part in a larger 12-week open-label trial. Patients were eligible if they had physician-diagnosed depression, and a Mini-Mental State Exam score ≥ 10. The physician or nurse coordinator obtained data from Healthcare professionals in daily contact with the patient to complete the Clinical Global Impression (CGI) scale, a modified 16-item Hamilton Depression Scale (HAM-D), and the Cornell Scale for Depression in Dementia (CSDD). Treatment-emergent adverse events were recorded. Results: Of the 50 patients enrolled at 23 sites, 72% completed the 12-week trial. The mean age of the participants was 89.3 years. The mean HAM-D score declined from 16.9 at baseline to 7.3 at endpoint (ITT, LOCF analysis) For the CSDD, the mean score declined from 15.1 to 7.1. The percentage of responders on the CGI-Improvement (CGI-1) scale increased at each assessment reaching 55% at endpoint. Only 10% of the patients discontinued treatment because of adverse events. There was a mean increase in weight of 1.32 lbs (0.6 kg) at day 84. Conclusion: Although lacking a placebo control, this naturalistic study suggests that mirtazapine orally disintegrating tablets were effective and well tolerated in this sample of depressed nursing home residents ≥85 years of age.

AB - Introduction: Treatment studies of depression in the very oldest patients are infrequent. For these reasons, this study of mirtazapine orally disintegrating tablets was carried out in nursing home residents ≥85 years old with physician-diagnosed depression. The naturalistic conditions of the study allowed us to include patients with cognitive impairment, concomitant medications and comorbid illness. Methods: This was a subgroup analysis of nursing home residents ≥85 years old who took part in a larger 12-week open-label trial. Patients were eligible if they had physician-diagnosed depression, and a Mini-Mental State Exam score ≥ 10. The physician or nurse coordinator obtained data from Healthcare professionals in daily contact with the patient to complete the Clinical Global Impression (CGI) scale, a modified 16-item Hamilton Depression Scale (HAM-D), and the Cornell Scale for Depression in Dementia (CSDD). Treatment-emergent adverse events were recorded. Results: Of the 50 patients enrolled at 23 sites, 72% completed the 12-week trial. The mean age of the participants was 89.3 years. The mean HAM-D score declined from 16.9 at baseline to 7.3 at endpoint (ITT, LOCF analysis) For the CSDD, the mean score declined from 15.1 to 7.1. The percentage of responders on the CGI-Improvement (CGI-1) scale increased at each assessment reaching 55% at endpoint. Only 10% of the patients discontinued treatment because of adverse events. There was a mean increase in weight of 1.32 lbs (0.6 kg) at day 84. Conclusion: Although lacking a placebo control, this naturalistic study suggests that mirtazapine orally disintegrating tablets were effective and well tolerated in this sample of depressed nursing home residents ≥85 years of age.

KW - Late life depression

KW - Mirtazapine

KW - Nursing home

UR - http://www.scopus.com/inward/record.url?scp=33749317195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749317195&partnerID=8YFLogxK

U2 - 10.1002/gps.1589

DO - 10.1002/gps.1589

M3 - Article

VL - 21

SP - 898

EP - 901

JO - International Journal of Geriatric Psychiatry

JF - International Journal of Geriatric Psychiatry

SN - 0885-6230

IS - 9

ER -